• Nuclear Medicine and Molecular Imaging
• /
• 제41권2호
• /
• pp.118-131
• /
• 2007

Neurotransmitter imaging with radiopharmaceuticals plays major role for understanding of neurological and psychiatric disorders such as Parkinson's disease and depression. Radiopharmaceuticals for neurotransmitter imaging can be divided to dopamine transporter imaging radiopharmaceuticals and serotonin trnasporter imaging radiopharmaceuticals. Many kinds of new dopamine transporter imaging radiopharmcaeuticals has a tropane ring and they showed different biological properties according to the substituted functional group on tropane ring. After the first clinical trials with $[^{123}I]{\beta}-CIT$, alkyl chain substituent introduced to tropane ring amine to decrease time for imaging acquisition and to increase selectivity. From these results, $[^{123}I]PE2I$, [18F]FE-CNT, $[^{123}I]FP-CIT$ and $[^{18}F]FP-CIT$ were developed and they showed high uptake on the dopamine transporter rich regions and fast peak uptake equilibrium time within 4 hours after injection. $[^{11}C]McN$ 5652 was developed for serotonin trnasporter imaging but this compound showed slow kinetics and high background radioactivity. To overcome these problems, new diarylsulfide backbone derivatives such as ADAM, ODAM, AFM, and DASB were developed. In these candidates, $[^{11}C]AFM$ and $[^{11}C]DASB$ showed high binding affinity to serotonin transporter and fast in vivo kinetics. This paper gives an overview of current status on dopamine and serotonin transporter imaging radiopharmaceuitcals and the development of new lead compounds as potential radiopharmaceuticals by medicinal chemistry.

• 대한핵의학회지
• /
• 제37권1호
• /
• pp.53-62
• /
• 2003

After the development of two major techniques - SPECT (Single Photon Emission Computed Tomography) and PET (Positron Emission Tomography) to image the human subjects in a three-dimensional direction in the 1980s, many radiotracers have been used for functional neuroimaging. Still it would be very important study to develop selective radiotracers for functional neuroimaging. New radiotracers will help to expand the knowledge of neurotransmitter systems and of the genetic contribution to receptor or transporter availability. Neurotransmitter depletion-restoration studies, the distribution of brain functions and their modulation by neurotransmitter system aid in better understanding and limiting the side effects of drugs used as well as newly developed. In audition, these radiotracers will be thus very useful to gain a better understanding in biochemical and pharmacological interactions in living human. This review mentions the introduction of radioligands for the functional neuroimaging. Although significant progress has been achieved in the development of new PET and SPECT ligands for in vivo imaging of those receptors and transporters, there are continuous needs of new diagnostic radioligands.

• Biomolecules & Therapeutics
• /
• 제30권2호
• /
• pp.191-202
• /
• 2022

Tetrazoles were designed and synthesized as potential inhibitors of triple monoamine neurotransmitters (dopamine, norepinephrine, serotonin) reuptake based on the functional and docking simulation of compound 6 which were performed in a previous study. The compound structure consisted of a tetrazole-linker (n)-piperidine/piperazine-spacer (m)-phenyl ring, with tetrazole attached to two phenyl rings (R1 and R2). Altering the carbon number in the linker (n) from 3 to 4 and in the spacer (m) from 0 to 1 increased the potency of serotonin reuptake inhibition. Depending on the nature of piperidine/piperazine, the substituents at R1 and R2 exerted various effects in determining their inhibitory effects on monoamine reuptake. Docking study showed that the selectivity of tetrazole for different transporters was determined based on multiple interactions with various residues on transporters, including hydrophobic residues on transmembrane domains 1, 3, 6, and 8. Co-expression of dopamine transporter, which lowers dopamine concentration in the biophase by uptaking dopamine into the cells, inhibited the dopamine-induced endoctytosis of dopamine D₂ receptor. When tested for compound 40 and 56, compound 40 which has more potent inhibitory activity on dopamine reuptake more strongly disinhibited the inhibitory activity of dopamine transporter on the endocytosis of dopamine D₂ receptor. Overall, we identified candidate inhibitors of triple monoamine neurotransmitter reuptake and provided a theoretical background for identifying such neurotransmitter modifiers for developing novel therapeutic agents of various neuropsychiatric disorders.

• 한국응용약물학회:학술대회논문집
• /
• 한국응용약물학회 1994년도 춘계학술대회 and 제3회 신약개발 연구발표회
• /
• pp.88-93
• /
• 1994

The mechanisms controlling the intensity and duration of synaptic transmission are numerous. Once an action potential reaches a nerve terminal, the stored neurotransmitters are released in a quantum fashion into the synaptic cleft. At that point neurotransmitters can act on post-synaptic receptors to elicit an action on the post-synaptic cell or net at so-called auto-receptors that are located on the presynaptic side and which often regulate the further release of the neutotransmitter. Whereas the action of the neurotransmitter receptors is regulated by desensitization phenomenon, the major mechanism by which the intensity and duration of neurotransmitter action is presumably regulated by either its degradation or its removal from the synaptic cleft. In the central nervous system, specialized proteins located in fe plasma membrane of presynaptic terminals function to rapidly remove neurotransmitters from the synaptic cleft in a sodium chloride-dependent fashion. These proteins have been referred to as uptake sites or neurotransmitter transporters. Once taken up by the plasma membrane transporters, neurotransmitters are repackaged into secretory vesicles by distinct transporters which depend on a proton gradient.

• Bulletin of the Korean Chemical Society
• /
• 제33권8호
• /
• pp.2597-2602
• /
• 2012

Novel 1,4-substituted piperazine derivatives 5, Series A and B were designed by fragment analysis and molecular modification of 4 selected piperazine-containing compounds which possess antidepressant activity. We synthesized new 39 analogues of Series A and 10 compounds of Series B, respectively. The antidepressant screening against DA, NE, and serotonin neurotransmitter uptake inhibition was carried out using the Neurotransmitter Transporter Uptake Assay Kit. The compounds in Series B showed relatively higher reuptake inhibitory activity for SERT, NET, and DAT than those in Series A. The length of spacer between the central piperazine core and the terminal phenyl ring substituted at the piperazine ring in Series B seems to exert an important role in the activity.

• 생명과학회지
• /
• 제18권7호
• /
• pp.940-946
• /
• 2008

신경전달물질을 수송하는 신경전달물질 수송체는 연접전막에서 신경전달물질의 농도를 조절한다. 신경세포에 발현하는 GATs들은 연접에서 억제성 신경전달물질인 GABA의 재흡수에 관여한다. GAT2/BGT1가 어떻게 연접전막에 안정적으로 존재하는지, 어떤 결합단백질과 결합하여 조절을 받는지는 알려져 있지 않다. 본 연구에서 효모 two-hybrid system을 사용하여 GAT2의 C-말단과 특이적으로 결합하는 mammalian Lin-7 (MALS)-2을 분리하였다. GAT2의 C-말단에 존재하는 "T-X-L"아미노산 배열이 MALS-2와의 결합에 필수적으로 관여하였다. 또한 이 단백질간의 결합을 pull-down assay로 확인한 결과 MALS는 glutathione S-transferase (GST)와는 결합하지 않으나 GST-GAT2와는 결합하였다. 또한 생쥐의 뇌 균질액에서 GAT2는 MALS와 함께 침강함을 면역침강으로 확인하였다. 이러한 결과들은 MALS가 GAT2와 결합하여 GAT2를 연접전막에서 안정화시키는 역할을 함을 시사한다.

• 생물정신의학
• /
• 제8권2호
• /
• pp.239-245
• /
• 2001

Objective : Dopamine transporter is member of family of Na/Cl dependent neurotransmitter transporter, 12 transmembrane domain, that has high substrate specificity, affinity. It is related with dopamine reuptake in presynaptic vesicle. DAT has a VNTR in its 3'-untranslated region(UTR). 3'-UTR VNTR polymorphism is related with modification of dopamine transmission. The association between with VNTR polymorphism and neuropsychiatric disorders such as alcohol dependence, and low activity ALDH has been studied, but their relationship is unclear. We study about association of 3'-UTR VNTR of DAT gene and G2319A and alcohol dependence. Method : Group of Korean subjects were studied with alcohol dependence(n=49 male) compared to mentally healthy controls(n=53 male). The peripheral blood sample was acquired, and Polymerase Chain Reaction(PCR) amplification, MspI procedure was done. Result : There was a significant difference between alcohol dependence group and normal control(genotype frequency p<0.05, allele frequency p<0.05) Allele A frequency and genotype(GG, GA) frequency was a significant difference between alcohol dependence group and normal control(p<0.05). Conclusion : Our study showed that genetic polymorphism of DAT1 G2319A had relation with alcohol dependence.

• 생명과학회지
• /
• 제22권9호
• /
• pp.1159-1165
• /
• 2012

${\gamma}$-Aminobutyric acid (GABA)는 신경세포 밖으로 분비된 후 GABA 수송체들(GATs)에 의하여 다시 신경세포 안으로 재흡수 된다. 그러나, GABA 수송체들이 어떻게 연접전막의 위치에 안정적으로 존재하는지 또한 어떤 단백질과 결합하여 조절을 받는지는 알려져 있지 않다. 본 연구에서 효모 two-hybrid system을 이용하여 betaine-${\gamma}$-aminobutyric acid transporter 1 (BGT-1/mGAT2)의 C-말단과 특이적으로 결합하는 Munc-18-interacting (Mint) 단백질을 분리하였다. BGT-1/mGAT2의 C-말단에 존재하는 "T-H-L" 아미노산배열은 Mint2와의 결합에 필수적으로 관여하였다. Mint2은 BGT-1/mGAT2와는 결합하지만, 다른 종류의 GAT와는 결합하지 않았다. 또한 HEK-293T 세포에 Mint2와 BGT-1/mGAT2을 동시에 발현시켜 면역침강한 결과 두 단백질은 같이 면역침강하였으며, 두 단백질은 세포 내에서 세포막 부위에 같이 존재함도 확인하였다. 이러한 결과들은 Mint2가 BGT-1/mGAT2와 결합하여 BGT-1/mGAT2을 조절하는 역할을 함을 시사한다.

• 대한방사성의약품학회지
• /
• 제2권2호
• /
• pp.113-117
• /
• 2016

As a neurotransmitter, serotonin plays important roles in brain. It relates various neuropsychiatric disorders such as anxiety, depression, schizophrenia. [$^{11}C$]DASB is a well-known PET tracer for serotonin transporter imaging. In this study, we synthesized [$^{11}C$]DASB in HPLC loop for simple and rapid production. Total synthesis time was about 40 minutes and the radiochemical purities were over 99%. The specific activity was $51.4GBq/{\mu}mole$ (n=16). [$^{11}C$]DASB showed highest uptake in mid-brain that serotonergic nerves are abundant and lowest uptake in cerebellum. In conclusion, we used HPLC loop method for [$^{11}C$]DASB labeling and this method is useful for production of $^{11}C$ labeled PET tracers.

• Clinical and Experimental Pediatrics
• /
• 제55권9호
• /
• pp.316-321
• /
• 2012

The ketogenic diet has been widely used and proved to be effective for intractable epilepsy. Although the mechanisms underlying its antiepileptic effects remain to be proven, there are increasing experimental evidences for its neuroprotective effects along with many researches about expanding use of the diet in other neurologic disorders. The first success was reported in glucose transporter type 1 deficiency syndrome, in which the diet served as an alternative metabolic source. Many neurologic disorders share some of the common pathologic mechanisms such as mitochondrial dysfunction, altered neurotransmitter function and synaptic transmission, or abnormal regulation of reactive oxygen species, and the role of the ketogenic diet has been postulated in these mechanisms. In this article, we introduce an overview about the expanding use and emerging trials of the ketogenic diet in various neurologic disorders excluding intractable epilepsy and provide explanations of the mechanisms in that usage.